266 related articles for article (PubMed ID: 35410419)
1. Real-world data reveals the complexity of disease modifying anti-rheumatic drug treatment patterns in juvenile idiopathic arthritis: an observational study.
Grazziotin LR; Currie G; Twilt M; Ijzerman MJ; Kip MMA; Koffijberg H; Benseler SM; Swart JF; Vastert SJ; Wulffraat NM; Yeung RSM; Marshall DA
Pediatr Rheumatol Online J; 2022 Apr; 20(1):25. PubMed ID: 35410419
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological treatment patterns in patients with juvenile idiopathic arthritis in the Netherlands: a real-world data analysis.
Kip MMA; de Roock S; Currie G; Marshall DA; Grazziotin LR; Twilt M; Yeung RSM; Benseler SM; Vastert SJ; Wulffraat N; Swart JF; IJzerman MJ
Rheumatology (Oxford); 2023 Feb; 62(SI2):SI170-SI180. PubMed ID: 35583252
[TBL] [Abstract][Full Text] [Related]
3. Factors determining resistance to conventional disease-modifying anti-rheumatic drug treatment in oligoarticular juvenile idiopathic arthritis.
Sener S; Aliyev E; Batu ED; Balik Z; Bayindir Y; Cam V; Basaran O; Bilginer Y; Ozen S
Clin Rheumatol; 2024 Jun; 43(6):2021-2026. PubMed ID: 38683443
[TBL] [Abstract][Full Text] [Related]
4. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation.
Shepherd J; Cooper K; Harris P; Picot J; Rose M
Health Technol Assess; 2016 Apr; 20(34):1-222. PubMed ID: 27135404
[TBL] [Abstract][Full Text] [Related]
5. Summary of AHRQ's Comparative Effectiveness Review of Disease-Modifying Antirheumatic Drugs for Children with Juvenile Idiopathic Arthritis.
McMahan R; Balfe LM; Greene L
J Manag Care Pharm; 2012; 18(1 Suppl B):1-16. PubMed ID: 22376227
[TBL] [Abstract][Full Text] [Related]
6. Clinical remission and subsequent relapse in patients with juvenile idiopathic arthritis: predictive factors according to therapeutic approach.
Castillo-Vilella M; Giménez N; Tandaipan JL; Quintana S; Modesto C
Pediatr Rheumatol Online J; 2021 Aug; 19(1):130. PubMed ID: 34419078
[TBL] [Abstract][Full Text] [Related]
7. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
[TBL] [Abstract][Full Text] [Related]
8. Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS).
Davies R; Carrasco R; Foster HE; Baildam EM; Chieng SEA; Davidson JE; Ioannou Y; Wedderburn LR; Thomson W; Hyrich KL
Semin Arthritis Rheum; 2016 Oct; 46(2):190-195. PubMed ID: 27422803
[TBL] [Abstract][Full Text] [Related]
9. Prescribing Patterns and Impact of Factors Associated with Time to Initial Biologic Therapy among Children with Non-systemic Juvenile Idiopathic Arthritis.
Yue X; Huang B; Hincapie AL; Wigle PR; Qiu T; Li Y; Morgan EM; Guo JJ
Paediatr Drugs; 2021 Mar; 23(2):171-182. PubMed ID: 33651370
[TBL] [Abstract][Full Text] [Related]
10. Decreasing trend in the incidence of serious pneumonias in Finnish children with juvenile idiopathic arthritis.
Salonen PH; Salonen JH; Säilä H; Helminen M; Linna M; Kauppi MJ
Clin Rheumatol; 2020 Mar; 39(3):853-860. PubMed ID: 31732822
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
12. Transition to adult rheumatology care is necessary to maintain DMARD therapy in young people with juvenile idiopathic arthritis.
Luque Ramos A; Hoffmann F; Albrecht K; Klotsche J; Zink A; Minden K
Semin Arthritis Rheum; 2017 Oct; 47(2):269-275. PubMed ID: 28583690
[TBL] [Abstract][Full Text] [Related]
13. A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis.
Bava C; Mongelli F; Pistorio A; Bertamino M; Bracciolini G; Dalprà S; Davì S; Lanni S; Muratore V; Pederzoli S; Rosina S; Schiappapietra B; Suffia C; Varnier G; Verazza S; Giancane G; Consolaro A; Ravelli A
Pediatr Rheumatol Online J; 2019 Jul; 17(1):50. PubMed ID: 31345226
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
[TBL] [Abstract][Full Text] [Related]
15. Comparative effectiveness and persistence of TNFi and non-TNFi in juvenile idiopathic arthritis: a large paediatric rheumatology centre in the USA.
Yue X; Huang B; Hincapie AL; Wigle PR; Li Y; Qiu T; Lovell DJ; Morgan EM; Guo JJ
Rheumatology (Oxford); 2021 Sep; 60(9):4063-4073. PubMed ID: 34469569
[TBL] [Abstract][Full Text] [Related]
16. Pregnancy outcomes in DMARD-exposed patients with juvenile idiopathic arthritis-results from a JIA biologic registry.
Drechsel P; Stüdemann K; Niewerth M; Horneff G; Fischer-Betz R; Seipelt E; Spähtling-Mestekemper S; Aries P; Zink A; Klotsche J; Minden K
Rheumatology (Oxford); 2020 Mar; 59(3):603-612. PubMed ID: 31412128
[TBL] [Abstract][Full Text] [Related]
17. Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND): results of the working group Polyarticular juvenile idiopathic arthritis.
Horneff G; Klein A; Ganser G; Sailer-Höck M; Günther A; Foeldvari I; Weller-Heinemann F
Pediatr Rheumatol Online J; 2017 Nov; 15(1):78. PubMed ID: 29116003
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with juvenile idiopathic arthritis (JIA) in a population-based cohort.
Zamora-Legoff JA; Krause ML; Crowson CS; Muskardin TW; Mason T; Matteson EL
Clin Rheumatol; 2016 Jun; 35(6):1493-9. PubMed ID: 26825065
[TBL] [Abstract][Full Text] [Related]
19. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Kurosawa R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2011 Dec; 21(6):572-8. PubMed ID: 21479889
[TBL] [Abstract][Full Text] [Related]
20. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
Otten MH; Anink J; Prince FH; Twilt M; Vastert SJ; ten Cate R; Hoppenreijs EP; Armbrust W; Gorter SL; van Pelt PA; Kamphuis SS; Dolman KM; Swart JF; van den Berg JM; Koopman-Keemink Y; van Rossum MA; Wulffraat NM; van Suijlekom-Smit LW
Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
